Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172534 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38895 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL31150922 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2315458 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29754090 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL23067650 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38896 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29355171 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL260109 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL187021 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2026-03-24 | — | — | US | claimed |
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | claimed |
| US-20240059724-A1 | DEVICE AND CASSETTE FOR PERFORMING A PLURALITY OF SYNTHESIS PROCESSES OF PREPARING A RADIOPHARMACEUTICAL IN SERIES | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2024-02-22 | — | — | US | claimed |
| CN-115323021-A | Method for regulating antibody glycoform and application thereof | 杭州奕安济世生物药业有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-113549667-A | Method for reducing galactosylation of antibody | 杭州奕安济世生物药业有限公司 | 2021-10-26 | — | — | CN | claimed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| US-5770407-A | Process for preparing nucleotide inhibitors of glycosyltransferases | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-23 | — | — | US | claimed |
| WO-1998025940-A1 | INHIBITORS OF GLYCOSYLTRANSFERASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-18 | — | — | WO | claimed |
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | OUT AND OUT CHEMISTRY S.P.R.L. (BE) | 2026-03-24 | — | — | US | disclosed |
| CN-115323021-B | Method for regulating antibody glycoform and application thereof | 创胜生物医药(杭州)有限公司 | 2025-12-05 | — | — | CN | disclosed |
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | disclosed |
| WO-2002048320-A2 | CRYSTAL STRUCTURES OF RETAINING GLYCOSYLTRANSFERASES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-06-20 | — | — | WO | disclosed |
| US-5770407-A | Process for preparing nucleotide inhibitors of glycosyltransferases | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998025940-A1 | INHIBITORS OF GLYCOSYLTRANSFERASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | LMNA 4786/4885L3MBTL1 3926/4885TDP1 3298/4885 |
| US-12583881-B2 | Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series | TMEM14C, FLT1, SLC6A12 | LMNA 2083/4885L3MBTL1 3757/4885TDP1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.